Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
暂无分享,去创建一个
Craig Wilson | Christopher P Cannon | Faiez Zannad | W. Cushman | C. Cannon | G. Bakris | F. Zannad | Alfonso T. Perez | W. White | S. Heller | R. Bergenstal | S. Nissen | S. Kupfer | C. Mehta | Simon R Heller | William B White | Steven E Nissen | Richard M Bergenstal | William C Cushman | George L Bakris | Stuart Kupfer | Alfonso T Perez | Penny R Fleck | Cyrus R Mehta | Craig A. Wilson | P. Fleck | A. Perez
[1] Christopher Jennison,et al. Interim analyses: the repeated confidence interval approach , 1989 .
[2] J. Nunnelee. Review of an article: The ADVANCE Collaborative Group. (2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM 2008;358:2560-2572. , 2008 .
[3] A. Goldfine. Assessing the cardiovascular safety of diabetes therapies. , 2008, The New England journal of medicine.
[4] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[5] M. Monami,et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials , 2011, Current medical research and opinion.
[6] Robert A Greevy,et al. Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus , 2012, Annals of Internal Medicine.
[7] E. Lonn,et al. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? , 2012, European heart journal.
[8] Deepak L. Bhatt,et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. , 2011, American heart journal.
[9] J. Holst,et al. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. , 1998, Diabetes.
[10] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[11] Fred S Apple,et al. Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.
[12] Michael E. Miller,et al. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes , 2011 .
[13] S. Schinner,et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[14] W. White,et al. Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus , 2013, Diabetes, obesity & metabolism.
[15] J. Meigs. Epidemiology of cardiovascular complications in type 2 diabetes mellitus , 2003, Acta Diabetologica.
[16] D. Drucker,et al. Cardiovascular biology of the incretin system. , 2012, Endocrine reviews.
[17] D. Patel,et al. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. , 2010, Current diabetes reviews.
[18] M. Monami,et al. Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials , 2013, Diabetes, obesity & metabolism.
[19] G. Paolisso,et al. New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly , 2008, Drugs & aging.
[20] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[21] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[22] S. Inzucchi,et al. Cardiovascular effects of the DPP-4 inhibitors , 2012, Diabetes & vascular disease research.